Chimerix, Inc.

Jazz Pharmaceuticals has agreed to buy Chimerx in a deal valued at about $935m, giving the company a near-to-market drug for a rare type of cancer. The transaction announced on 5 March comes roughly a

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

Cross-border M&A remained largely resilient in 2022, with a return to healthy pre-pandemic levels, and while the types of deals we see in 2023 may evolve, many observers believe that deal volume will

Since it began spreading in the spring and migrated to the US shortly thereafter, monkeypox has yet to explode from an outbreak into a bigger epidemic, let alone a pandemic, and infection rates are al